News | 14 June 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
These five oxygen plants with a total capacity of 3,840 cubic meters of oxygen per day have been donated to Madhya Pradesh, Maharashtra, and Gujarat
With the acquisition of these further shares, TWPL has now become company's subsidiary.
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
The study was conducted in patients with mild to moderate COVID-19
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
The Prime Minister announced that 21st June onwards, the Government of India will provide free vaccines to all Indian citizens above 18 years of age
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Subscribe To Our Newsletter & Stay Updated
